Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Cell and Gene Therapy Market Size to Reach 6,570.0 Million in 2027 | Rising Use of Gene Therapy to Treat Rare Diseases, Rapid Product Approvals and Growing Funding are Some Key Factors Driving Industry Demand, says Emergen Research

This image opens in the lightbox

News provided by

Emergen Research

28 Jul, 2021, 11:07 GMT

Share this article

Share toX

Share this article

Share toX

VANCOUVER, B.C, July 28, 2021 /PRNewswire/ -- The global cell and gene therapy market size is expected to reach USD 6,570.0 million in 2027 at a CAGR of 19.8%, according to the latest report by Emergen Research. Market revenue growth is majorly driven by increasing application scope of cell and gene therapies to treat severe and chronic diseases such as cancer, obesity, genetic aberrations, diabetes and related complications, and other rare diseases. In addition, rising number product approvals by the FDA and other regulatory bodies and increasing investment and funding to accelerate research in cell and gene therapy are some other key factors further fueling revenue growth of the market.

Cell and gene therapy are rapidly progressing research fields in biomedical discipline that aim to treat, arrest progression of diseases, and potentially cure them. These therapies can also effectively alleviate the underlying cause of genetic and acquired diseases. Cell therapy treats diseases by restoring or alerting cells and it functions by cultivating or modifying cells outside the body before they are injected into the patient's body. Cell therapy covers all aspects of cellular immunotherapies, cancer medications, and other therapies that include cells from donors and recipients for cell therapies. Research and development related to gene and cell therapy has accelerated at a fast-rate across the globe, with increasing number of products progressing to clinical trials and development. Advancements in chimeric antigen receptor T-cell therapy has increased the opportunity for development of novel drugs and therapeutics to treat rare and chronic diseases. This is a key factor expected to further fuel revenue growth over the forecast period.

Free sample PDF Copy of the Report available@ https://www.emergenresearch.com/request-sample/27

Increasing prevalence of cancer and genetic diseases across the globe and availability of cell and gene therapeutic products in the market are some other key factors expected to contribute to the revenue growth over the forecast period. However, high costs associated with gene and cell therapy, increasing burden of expenditure on healthcare facilities, and lack of knowledge regarding cell and gene therapy are some key factors expected to restrain market growth to a certain extent over the forecast period.

Some Key Highlights in the Report:

  • Large B-cell lymphoma segment accounted for the largest revenue share in the global market in 2019 and is expected to register significant revenue growth over the forecast period. Revenue growth can be attributed to increasing use of gene therapy to develop a personalized treatment approach to treat large B-cell lymphoma among adults.
  • Retrovirus and gammaretrovirus segment revenue is expected to expand at a robust revenue CAGR over the forecast period attributed to rising application of retrovirus vectors to permanently modify or alter host genome owing to their high capability of altering RNA genome to DNA genome to readily integrate into the target cell.
  • North America is expected to account for largest revenue share in the global market over the forecast period owing to rapid advancements in gene and cell therapy due to increasing funding and investment, rising number of FDA approvals, presence of key companies, establishment of state-of-the-art facilities, and high number of clinical trials for gene therapy in the region.
  • Key companies in the market include Spark Therapeutics LLC, Novartis AG, Gilead Sciences Inc., Bluebird Bio, GlaxoSmithKline, Celgene Corporation, Shire PLC, Sangamo Biosciences, Voyager Therapeutics, and Dimension Therapeutics, among others.
  • In March 2019, Biogen announced the acquisition of Nightstar Therapeutics to design and develop clinical pipeline of gene therapy candidates for ophthalmic diseases. Nighstar Therapeutics is a gene therapy company that is engaged in developing novel and effective treatments for patients suffering from rare and inherited retinal diseases that can lead to blindness if untreated.
  • In July 2021, AGC Biologics announced the acquisition of a cell and gene therapy commercial manufacturing facility from Novartis Gene Therapies to expand its end-to-end cell and gene therapy offering.
  • In July 2021, Ashfield, which is a part of UDG Healthcare, launched an end-to-end cell and gene therapy network, EmerGENE, to help small and medium biotech companies to commercialize their discoveries – from design and development to clinical trials to commercialization.

Buy your Exclusive copy [Make Payment ]@ https://www.emergenresearch.com/select-license/27

For the purpose of this report, Emergen Research has segmented the global cell and gene therapy market on the basis of indication, vector type, and region:

Indication Outlook (Revenue, USD Million; 2017-2027)

  • Acute Lymphoblastic Leukemia (ALL)
  • Inherited Retinal Disease
  • Large B-Cell Lymphoma
  • ADA-SCID
  • Others

Vector Outlook (Revenue, USD Million; 2017-2027)

  • Lentivirus
  • AAV
  • Retrovirus & Gammaretrovirus
  • Modified Herpes Simplex Virus
  • Adenovirus
  • Non-Viral Plasmid Vector

Have a look at Report Description and Table of Contents of Market Research Report@ https://www.emergenresearch.com/industry-report/cell-and-gene-therapy-market

Regional Outlook (Revenue, USD Million; 2017-2027)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • BENELUX
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Israel
    • Rest of MEA

Explore more reports offered by Emergen Research:

Organ on a Chip Market By Type (Liver-on-Chip, Multiple Organs-on-Chips, Kidney-on-Chip, Heart-on-Chip, Lung-on-Chip, Intestine-on-Chip), By Application (Drug Discovery, Physiological Model Development, Toxicology Research), By End-Use (Pharmaceutical Firms, Research Institutes, Personal Care Industry), and By Region Forecast to 2028

RNA Transcriptomics Market By Product (Reagents, Instruments, Software, Service), By Technology (Microarrays, Polymerase Chain Reaction, RNA Sequencing, RNA Interference), By Application (Clinical Diagnostics, Toxicogenomics, Drug Discovery, Comparative Transcriptomics), By End-Use (Hospitals, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations). and By Region

Slide Stainers Market By Product (Reagents, Consumables & Accessories, Equipment), By Technology (Hematoxylin and Eosin, Immunohistochemistry, In Situ Hybridization, Cytology, Microbiology, Hematology, Special Stains), By End-Use (Hospitals and Diagnostic Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Other), and By Region Forecast to 2028

Flow Imaging Microscopy Market By Sample Type (Large Biomolecule, Small Biomolecules, Liquid & Viscous Samples, Microfibers and Nano fibers, Others), By Sample Dispersion (Wet Dispersion, Dry Dispersion), By End-Use (Biotechnology Companies, Pharmaceutical Companies, Water Testing Laboratories, Food & Beverage Companies, Research & Academia, Metal Manufacturing, Chemical & Petrochemical Industries), and By Region Forecast to 2028

Bioanalytical Testing Services Market By Type (Cell-based Assays, Virology Testing, Method Development Optimization, and Validation, Serology Immunogenicity, and Neutralizing Antibodies, Pharmacokinetic Testing, Biomarker Testing, Others), By Application (Neurology, Oncology, Infectious Diseases, Cardiology, Gastroenterology, Other), By End-User (Biopharmaceutical and Pharmaceutical Companies, Contract Development and Manufacturing Organizations, Contract Research Organizations), and By Region Forecast to 2028

Laboratory Centrifuges Market By Product (Equipment, Accessories), By Model (Benchtop Centrifuges, Floor-standing Centrifuges), By Usage (General Purpose Centrifuges, Preclinical Centrifuges, Clinical Centrifuges), By Rotor Design (Fixed-angle Rotors, Vertical Rotors, Swinging-bucket Rotors, Other Rotors), By Application (Diagnostics, Cellomics, Genomics, Microbiology, Blood Component Separation, Proteomics, Other), By End-Use (Hospitals, Academic & Research Institutions, Biotechnology & Pharmaceutical Companies), and By Region Forecast to 2028

Orthopedic Biomaterial Market By Material Type (Polymers, Ceramics & Bioactive Glasses, Composites, Metal, Calcium Phosphate), By Application (Orthopedic Implants, Orthobiologics, Joint Reconstruction/Replacement, Bio-resorbable Tissue Fixation, Visco Supplementation), By End-Use (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), and By Region, Forecast to 2028

About Emergen Research 

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Facebook | LinkedIn | Twitter | Blogs
Read Full Press Release@ https://www.emergenresearch.com/press-release/global-cell-and-gene-therapy-market

Logo: https://mma.prnewswire.com/media/1579538/Emergen_Research_Logo.jpg  

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.